Birtas Atesoglu, E. Et Al. 2023. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data. Hematological Oncology , vol.41, no.4 , 663-673.

Birtas Atesoglu, E., Gulbas, Z., UZAY, A., ÖZCAN, M., ÖZKALEMKAŞ, F., Dal, M. S., ... Kalyon, H.(2023). Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data. Hematological Oncology , vol.41, no.4, 663-673.

Birtas Atesoglu, Elif Et Al. "Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data," Hematological Oncology , vol.41, no.4, 663-673, 2023

Birtas Atesoglu, Elif B. Et Al. "Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data." Hematological Oncology , vol.41, no.4, pp.663-673, 2023

Birtas Atesoglu, E. Et Al. (2023) . "Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data." Hematological Oncology , vol.41, no.4, pp.663-673.

@article{article, author={Elif Birtas Atesoglu Et Al. }, title={Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data}, journal={Hematological Oncology}, year=2023, pages={663-673} }